Sanofi to infuse Euro 400 million in new vaccine production site
Paris: Sanofi has recently announced a EURO 400 million investment over five years to create a unique vaccine production center in Singapore, pushing the boundaries of operations through cutting edge manufacturing and digital technologies.
In partnership with the Singapore Economic Development Board (EDB), the new site will mainly supply the Asian region and complement existing manufacturing capacities in Europe and North America.
The investment furthers Sanofi's commitment to driving the future of vaccines by expanding manufacturing capabilities to ensure quality and scale, while responding to the risk of future pandemics. The project is expected to create up to 200 local jobs and enhance Singapore's position as a regional innovation hub for the healthcare industry.
"As a major healthcare player, it's our responsibility to act and to meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics," said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. "We are very pleased by the strong collaboration with the Singapore Economic Development Board to achieve this exciting milestone."
"Sanofi's decision to locate its first-in-Asia digitally-enabled vaccine production center in Singapore, to supply markets in the region and beyond, is an endorsement of Singapore's position as a leading centre for advanced manufacturing" said Dr Beh Swan Gin, Chairman, EDB. "EDB will continue to promote digitalization, automation and innovation to transform the manufacturing sector and create good jobs for Singaporeans."
This factory will be designed around a central unit housing several fully digitalized modules that allow production of three to four vaccines simultaneously, versus only one in current industrial sites. In addition, the factory will have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types This modularity and flexibility will allow the production of a specific vaccine to be prioritized in a faster timeframe depending on public health needs.
The project is currently entering its design phase with construction expected to begin in Q3 2021. The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed.
In the context of Sanofi's environmental strategy, the site is designed to be carbon-neutral, and to drastically reduce both resource consumption and waste production.
Read also: Sanofi gets USFDA nod for Sarclisa, Carfilzomib, Dexamethasone combo to treat multiple myeloma
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.